Professional Documents
Culture Documents
Experimental Epidemiology: Randomized & Non-Randomized Control Trial.
Experimental Epidemiology: Randomized & Non-Randomized Control Trial.
Dr Jatin Chhaya
Community Medicine Department
SBKS MIRC
Research studies
a) Drawing of a protocol.
b) Selecting reference population (unit of study).
c) Randomization (allocation into experimental and
control group).
d) Manipulation (intervention).
e) Follow-up.
f) Assessment of outcome.
g) Reporting.
1. Drawing of Protocol
This means specifying the following basic
information before the commencement of the clinical
trial. They are:
Aims and objectives of the study.
Criteria for the selection of study group and
control group.
Size of the sample
Procedures for allocation into study group and
control group.
Intervention to be done (Methodology of
procedure).
The cooperation of the participants till the end of
2. Selection of Reference Population
Reference population is the target population,
to which the results if found successful, are
expected to be applicable.
Reference population, depending upon the
study, could be all suffering from a particular
disease under experiment, e.g. TB/leprosy
patients for new therapy/new regimen or
patients with hernia for new surgical
procedure, etc
3. Randomization (Selection of Study and
Control Group)
This is the ‘Heart’ of the clinical trial. Every
individual has an equal chance of being selected
into either study group or control group, from
the reference population.
Selection of study group (Experimental group):
It is the actual population (or volunteers) derived
from the reference population randomly,
participating in the experiment, still retaining the
same characteristics as the reference population.
Randomization eliminates bias and allows
comparability.
The study group should fulfil the following three
criteria:
It should be ‘Representative’ of the reference
population.
They must give ‘informed consent’, after being
fully informed about the procedure and possible
dangers of the trial.
They must be ‘Susceptible’ to the disease under
study. (i.e. qualified or eligible) Example:
Suppose the trial is on the effect of a new drug
for Anemia, the volunteers must be anemic.
4. Selection of control group.
Another group of the same size as that of the
study group is selected at random from the
reference population, maintaining the similar
characteristics (e.g. age, sex, occupation,
literacy level, income, etc.) as that of the study
group but they do not receive intervention.
5. Manipulation or Intervention
The next step is to intervene or manipulate the
study group by the deliberate application or
withdrawal or reduction of the causal factor,
i.e. new drug, whereas the control group is put
on the inert (or placebo) or the old drug
6. Follow-up
This consists of examination of both the
groups at defined intervals of time
At times, some losses occur to follow-up due
to death or migration or non-cooperation of the
participants.
This is known as ATTRITION. .
7. Assessment of Outcome
This is the final step of clinical trial. The
results may be positive (e.g. the new drug is
better and safer) or may be negative (e.g. the
new drug is not good and/or more hazardous).
The incidence of results (positive or negative)
is compared in both the groups and the
differences are tested for the tests of
significance.
Bias may arise from three sources resulting in errors, as
follows:
1. Subject variation: Patients may report
better/improvement, if they know that they are under
new treatment.
2. Observer bias: Is made by the investigator while
observing.
3. Bias in evaluation: Is made by the investigator
subconsciously.
In order to overcome these errors and bias, a technique
known as ‘Blinding’ is adopted, which is done in three
ways.
4. Single blind trial
5.Double blind trial
Single blind trial: In this type, the participants do not
know whether they belong to study group or control
group. That means they do not know whether they are
receiving new drug or the placebo. However, the
investigator knows who belong to which group. This
trial helps to overcome subject variation.
Double blind trial: In this type, neither the
investigator, (Doctor) nor the participants (patients)
know the group allocation and the treatment (new drug)
received. However, statistician knows it. He assigns the
code numbers and hands over the drugs with code
number to the investigator (doctor) indicating which
one to be given to whom. At the end, the results are
given back to statistician along with the code numbers
for analysis. He will decode and analyse the results.